The National Institutes of Health (NIH) has recently announced a significant change to its funding structure, reducing indirect research cost reimbursements to approximately 15% across all NIH grants. This decision follows a broader push to limit funding for these costs, which has raised concerns among researchers about its long-term consequences, particularly in specialized fields like type 1 diabetes research.
While a judge temporarily blocked President Trump’s executive order to enforce these cuts, experts fear that the policy could disrupt vital medical progress if upheld in the future. Aaron J. Kowalski, Ph.D., CEO of Breakthrough T1D, spoke with Managed Healthcare Executive, emphasizing that the funding reductions could severely hinder medical advancements, particularly for the NIH’s Special Diabetes Program, which funds critical research into type 1 diabetes.
Kowalski explained that many institutions, including prominent state universities, rely heavily on NIH funding, and these cuts could force a slowdown in research across a variety of fields, including cancer and Alzheimer’s. “I got my Ph.D. at Rutgers. We don’t have a Harvard endowment, and it will mean research will grind to a halt,” Kowalski remarked.
The NIH’s Special Diabetes Program, which has been pivotal in the fight against type 1 diabetes since its inception in 1998, has helped fund numerous collaborative research efforts, including:
- Clinical Islet Transplantation Consortium
- Collaborative Islet Transplant Registry
- Diabetes Research in Children Network
- Diabetic Retinopathy Clinical Research Network
- Epidemiology of Diabetes Interventions and Complications
- Genetics of Kidneys in Diabetes
- Search for Diabetes in Youth
- Environmental Determinants of Diabetes in the Young
- Type 1 Diabetes Genetics Consortium
- Type 1 Diabetes TrialNet
Managed by the National Institute of Diabetes and Digestive and Kidney Diseases, this program has contributed to groundbreaking advancements in type 1 diabetes research. However, Kowalski fears that these cuts could slow or even halt future progress.
The broader implications of the NIH’s funding cuts extend beyond diabetes research, potentially affecting a wide range of scientific fields that rely on the agency’s financial support.
Related topics:
Kevin Frankish Champions the ‘Above the Bias’ Campaign to End Diabetes Stigma
Reversing Type 2 Diabetes: Experts Share Insights
